Abstract
Colistin is a polymyxin group antibiotic, and colistimethate-sodium is the prodrug form of colistin and is inactive. Colistin is often the last optional drug for nosocomial infections caused by multidrug-resistant gram-negative microorganisms. We present a case of asymptomatic eosinophilia due to systemic colistin therapy. The increasing trend of absolute eosinophil counts appeared with recurrent colistin therapy and decreased when colistin was discontinued. The Naranjo Adverse Drug Reaction Probability Scale score was 7, and this score was classified as 'probable' for this case. Clinicians should consider this drug reaction in a patient with eosinophilia and avoid unnecessary laboratory tests and treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
